TARA-002

Bacterial immunotherapy

Phase 3underway

Evidence outlook · registrational

Non-Muscle Invasive Bladder Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-04.

Company guidance: regulatory filing expected second half of 2027 (Protara Therapeutics, 6 Nov 2026). “Based on engagement with the FDA under Breakthrough Therapy designation, the Company expects to initiate a rolling BLA submission for TARA-002 in the second half of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Non-Muscle Invasive Bladder Cancer
Phase 2 (2)
Non-Muscle Invasive Bladder Cancer
NCT05951179 · Protara Therapeutics
2023-09-15 – 2032-03 · Non-muscle Invasive Bladder Cancer
What this study did
Other / comorbidity
NCT05871970 · Protara Therapeutics
2023-10-18 – 2027-05 · Lymphatic Malformation
What this study did
Phase 1 (2)
Non-Muscle Invasive Bladder Cancer
NCT05085977 · Protara Therapeutics
2022-03-10 – 2024-10-30 · Non-muscle Invasive Bladder Cancer
What this study did
NCT05085990 · Protara Therapeutics
2023-05-08 – 2024-09-12 · Non-muscle Invasive Bladder Cancer
What this study did

Competitive landscape

This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TARA-002: this drugPhase 3Bacterial immunotherapyInnate and adaptive immune activation (inactivated Streptococcus pyogenes)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-1501Phase 3UndisclosedIL-15not yet gradedNo reviewed efficacy summary in this indication
TAR-210Phase 3Intravesical Drug Delivery System (erdafitinib)—not yet gradedNo reviewed efficacy summary in this indication
PF-08052667Phase 1Antibody–drug conjugateIntegrin beta-6 (ITGB6)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TARA-002 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Lymphatic MalformationRecruiting
Est. primary completion 2026-12 · NCT05871970 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Phase 3Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2028-04 · NCT07480356 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 2Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2031-10 · NCT05951179 · CT.gov ↗
What to watch

See the full readout calendar ↗